A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

scientific article published on April 2012

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1586/ERV.12.20
P698PubMed publication ID22551023
P5875ResearchGate publication ID224886870

P2093author name stringScott Vuocolo
Stephen E Goldstone
P2860cites workHuman Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic ReviewQ22306450
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesQ24614644
Trends in the incidence of invasive and in situ vulvar carcinomaQ24825208
Global cancer statistics, 2002Q27860562
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccineQ28255537
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenQ28271727
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesionsQ28301685
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysisQ28305321
Epidemiologic classification of human papillomavirus types associated with cervical cancerQ29616213
Classification of papillomavirusesQ29618731
Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasiaQ31035514
External genital warts: diagnosis, treatment, and prevention.Q31112715
Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseasesQ33154439
Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult managementQ33259401
Human papillomavirus-related disease in men: not just a women's issueQ33855416
Chapter 1: HPV in the etiology of human cancerQ34562937
Chapter 6: Epidemiology and transmission dynamics of genital HPV infectionQ34562942
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesQ34627305
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisQ34642665
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university studentsQ34705438
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.Q34801294
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsQ34910428
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with menQ34910475
Human papillomavirus vaccines and prevention of cervical cancerQ35640262
Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesisQ35746826
The costs of treating external genital warts in England and Wales: a treatment pattern analysisQ35861590
Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United StatesQ35988721
Worldwide burden of gynaecological cancer: the size of the problemQ36344510
Prevention of recurrent respiratory papillomatosis: role of HPV vaccinationQ36555070
Chapter 2: The burden of HPV-related cancersQ36584354
Chapter 15: HPV vaccine use in the developing worldQ36584364
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 diseaseQ36584416
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upQ36612475
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisQ36670753
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirusQ36717732
The economic burden of noncervical human papillomavirus disease in the United StatesQ36740006
Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003.Q37220744
Human papillomavirus prevalence and type distribution in penile carcinomaQ37586655
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implicationsQ37622609
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccineQ37642538
HPV vaccine and males: issues and challengesQ37686833
Post-licensure monitoring of HPV vaccine in the United StatesQ37699644
Pathology and epidemiology of HPV infection in femalesQ37715406
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.Q37745678
Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review.Q37850481
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsQ38383523
International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomasQ38503187
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE studyQ39700791
Burden of cervical cancer in Europe: estimates for 2004.Q40232407
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesQ40430523
Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.Q40448304
Prognostic significance of human papillomavirus DNA in vulvar carcinomaQ40510041
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young womenQ43655015
Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men.Q44028516
The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassayQ44995543
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyQ45206974
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccineQ45212845
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineQ45404033
Natural history of vaginal intraepithelial neoplasiaQ45736749
HPV vaccine against anal HPV infection and anal intraepithelial neoplasiaQ46421186
Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000.Q46645214
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionQ46654947
Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.Q46870430
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publicationQ47860026
The health and economic burden of genital warts in a set of private health plans in the United StatesQ47887573
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.Q48718586
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.Q50627829
The psychosocial impact of human papillomavirus infection: implications for health care providers.Q51114247
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.Q51257523
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.Q54495496
Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.Q54569323
Oropharyngeal carcinoma related to human papillomavirusQ56532842
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital LesionsQ56770293
P433issue4
P304page(s)395-406
P577publication date2012-04-01
P1433published inExpert Review of VaccinesQ15756339
P1476titleA prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
P478volume11